Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II , Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Effects of SC0245 in Combination With Irinotecan in Patients With ES-SCLC

Next Previous
X
Search
Trial Profile

A Phase Ib/II , Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Effects of SC0245 in Combination With Irinotecan in Patients With ES-SCLC

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; SC 0245 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biocity Biopharmaceutics

    • Most Recent Events

    • 04 Jun 2024 Results (n=15, As of the data cut-off-date (December 21, 2023)) assessing safety, efficacy and Pharmacokinetics were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 11 Jul 2023 Status changed from not yet recruiting to recruiting.
    • 17 Feb 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top